Akari Therapeutics (NASDAQ: AKTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Earnings and Valuation

This table compares Akari Therapeutics and Sarepta Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akari Therapeutics N/A N/A -$18.14 million ($0.28) -18.04
Sarepta Therapeutics $5.42 million 624.24 -$267.26 million ($2.04) -25.66

Akari Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Akari Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akari Therapeutics and Sarepta Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akari Therapeutics N/A -152.12% -102.69%
Sarepta Therapeutics -112.08% -51.72% -43.55%

Risk & Volatility

Akari Therapeutics has a beta of -9.06, suggesting that its share price is 1,006% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Insider and Institutional Ownership

21.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 82.0% of Sarepta Therapeutics shares are owned by institutional investors. 61.8% of Akari Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Akari Therapeutics and Sarepta Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics 0 1 2 0 2.67
Sarepta Therapeutics 0 4 16 0 2.80

Akari Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 73.27%. Sarepta Therapeutics has a consensus price target of $66.11, indicating a potential upside of 26.28%. Given Akari Therapeutics’ higher possible upside, equities research analysts plainly believe Akari Therapeutics is more favorable than Sarepta Therapeutics.

Summary

Sarepta Therapeutics beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.